Two Sigma Investments LP Raises Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Two Sigma Investments LP raised its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 4.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,660,509 shares of the company's stock after purchasing an additional 63,211 shares during the quarter. Two Sigma Investments LP owned 0.42% of Recursion Pharmaceuticals worth $11,225,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in RXRX. Accel Wealth Management purchased a new position in shares of Recursion Pharmaceuticals in the fourth quarter worth $310,000. Man Group plc bought a new stake in Recursion Pharmaceuticals in the fourth quarter worth $479,000. Rockefeller Capital Management L.P. increased its position in Recursion Pharmaceuticals by 323.1% during the fourth quarter. Rockefeller Capital Management L.P. now owns 281,922 shares of the company's stock valued at $1,906,000 after acquiring an additional 215,283 shares during the last quarter. Institute for Wealth Management LLC. bought a new position in Recursion Pharmaceuticals during the fourth quarter valued at $3,928,000. Finally, Invesco Ltd. increased its position in Recursion Pharmaceuticals by 54.6% during the fourth quarter. Invesco Ltd. now owns 178,619 shares of the company's stock valued at $1,207,000 after acquiring an additional 63,068 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Trading Up 2.4%

Shares of NASDAQ RXRX traded up $0.11 during trading on Thursday, hitting $4.51. 10,306,889 shares of the company were exchanged, compared to its average volume of 13,537,664. The company has a fifty day moving average price of $5.00 and a 200-day moving average price of $6.45. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The firm has a market capitalization of $1.83 billion, a PE ratio of -2.94 and a beta of 0.99. Recursion Pharmaceuticals, Inc. has a 12-month low of $3.79 and a 12-month high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The firm had revenue of $14.75 million during the quarter, compared to analyst estimates of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business's revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.39) earnings per share. As a group, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on RXRX shares. Needham & Company LLC cut their price objective on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Morgan Stanley decreased their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, Leerink Partners decreased their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $7.60.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.